REPL (Replimune Group, Inc.) Rasio Nilai Pasar marang Nilai Buku

Simbol resmi perusahaan Replimune Group, Inc. (REPL)

The available price action for Replimune Group, Inc. (REPL) reflects the dynamics of a company developing immune-based oncology drugs. The business faces uncertainty regarding test results and the risk of equity dilution, with the metric standing at 9.82. The share price depends on scientific breakthroughs rather than economic cycles. Operations are supplemented by strict compliance with bio-waste disposal standards and chemical controls.

Replimune Inc. (REPL): Rasio Kapitalisasi marang Nilai Buku saka 04.07.2022 nganti 27.10.2026

Rincian metrik keuangan lan pasar Replimune Group Inc (REPL)

- rega lan prakiraan konsensus rega:
Bagan rega Replimune Group, Inc.|REPL - Bagan rega target
- data kapitalisasi pasar:
Nilai pasar Replimune Corp|REPL - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Replimune|REPL - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku replimune.com|REPL - Gunggung Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Replimune Group, Inc.|REPL - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Replimune Corp|REPL - Utang perusahaan|Rasio utang marang kapitalisasi buku Replimune Corp
Pambiji fundamental:Replimune Group, Inc.
Produk merek Replimune Corp

This indicator measures the market value premium over net assets, reflecting investor expectations regarding the future value of the business relative to its current tangible asset base. Analyzing the market-to-book ratio chart for Replimune Group, Inc. (REPL) reveals how ownership of a cGMP facility and an R&D center creates a fundamental basis that ensures the company's operational stability amid a high market valuation of its innovative potential.

Analisis pesaing

ImmunityBio, Inc. (IBRX) - Rasio Nilai Pasar marang Nilai Buku|IMCR (immunocore.com) - Rasio Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku JANX (Janux Therapeutics, Inc.)|Koefisien Nilai Pasar marang Nilai Buku RCUS|Rasio Nilai Pasar marang Nilai Buku Zymeworks Corp ZYME|Rasio Kapitalisasi marang Nilai Buku Tango Therapeutics Corp (TNGX)|Iovance Biotherapeutics - Rasio Kapitalisasi Pasar marang Nilai Buku|immatics.com - Rasio Kapitalisasi marang Aset Bersih|XNCR (Xencor) - Rasio Nilai Pasar marang Nilai Buku|CMPX: Koefisien Nilai Pasar marang Nilai Buku|Lyell Immunopharma Inc (LYEL) - Rasio Nilai Pasar marang Nilai Buku|IPHA (Innate Pharma S.A) - Rasio Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku PYXS (Pyxis Oncology Inc.)|Koefisien Nilai Pasar marang Nilai Buku Compugen Limited|IOBT: Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Ekuitas Sutro Biopharma Inc. STRO|INKT: Rasio Kapitalisasi marang Aset Bersih|HOWL - Koefisien Nilai Pasar marang Nilai Buku|Rasio Kapitalisasi marang Aset Bersih Immix (IMMX)|ALXO - Nilai Pasar marang Nilai Buku|Cue Biopharma - Rasio Kapitalisasi Pasar marang Nilai Buku|PDSB (PDS Biotechnology Corporation) - Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku SONN|Rasio Kapitalisasi marang Aset Bersih MAIA|Rasio Nilai Pasar marang Nilai Buku LIMN (Liminatus Pharma)|Rasio Kapitalisasi marang Aset Bersih lavatherapeutics.com LVTX|Rasio Kapitalisasi marang Aset Bersih NXTC (NextCure)|Leap Therapeutics Inc - Rasio Kapitalisasi Pasar marang Nilai Buku|Intensity Tx (INTS) - Rasio Nilai Pasar marang Nilai Buku|SNSE: Rasio Kapitalisasi marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku TOVX|Koefisien Nilai Pasar marang Nilai Buku Gritstone bio|Kineta - Rasio Kapitalisasi marang Aset Bersih|Rasio Nilai Pasar marang Ekuitas NexImmune Inc (NEXI)|Rasio Kapitalisasi marang Aset Bersih Turnstone Biologics|Multiplikator Kapitalisasi Pasar marang Nilai Buku Vaccinex Inc (VCNX)|Rasio Kapitalisasi Pasar marang Nilai Buku Harpoon Therapeutics